<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563288</url>
  </required_header>
  <id_info>
    <org_study_id>GeorgePapanikolaouHospital</org_study_id>
    <nct_id>NCT02563288</nct_id>
  </id_info>
  <brief_title>Esmolol Versus Dexmedetomidine During Intracranial Procedures</brief_title>
  <official_title>Comparison of Esmolol and Dexmedetomidine on Sympathetic Control During Intracranial Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Papanicolaou Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>George Papanicolaou Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing intracranial procedures may experience severe hypertension and
      tachycardia due to intracranial hypertension and to increased release of adrenaline.
      Preventing perioperative sympathetic activity is of great importance. A common technique is
      using b-blockers like esmolol, which effectively block perioperative hemodynamic changes
      during intracranial surgery. A2 agonists, like Dexmedetomidine-Dex are now being used as a
      component of a balanced anesthesia during neurosurgical procedures. This study aimed to
      evaluate whether esmolol or dex attenuates perioperative changes in patients undergoing
      elective craniotomy with fast track neuroanesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients scheduled for elective craniotomy are randomized to receive Dex 1γ/Kg over 10
      minutes following by continuous infusion of Dex 0.7γ/Kg (group D) or esmolol 500mcg/Kg over 5
      min following by continuous infusion of 300mcg/Kg/min (group E). Patients in both groups are
      subjected to a standardized anesthesia comprising of induction with propofol, fentanyl,
      rocuronium, and maintained with Oxygen-air: 1/1, sevoflurane and bolus fentanyl in order to
      access the same level of anesthesia (BIS 40-50). The hemodynamic variables at various stages
      of surgery (HR-heart rate, MAP-Mean arterial pressure) and recovery characteristics are also
      recorded. It is also performed monitoring of cerebral oximetry (INVOS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic arterial pressure- mean arterial pressure (mmHg)</measure>
    <time_frame>every 15minutes, starting from the induction in anesthesia through surgery completion and up to first 24 postoperative hours.</time_frame>
    <description>Status of patients during emerge from anaesthesia after intracranial surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <condition>Intracranial Neoplasms</condition>
  <arm_group>
    <arm_group_label>Esmolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esmolol 500mcg/kg before induction in anesthesia following by 300mcg/Kg/min until extubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine 1mcg/Kg following by 0.7mcg/Kg/h until end of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>effect of esmolol on intraoperative sympathetic control and on extubation conditions.</description>
    <arm_group_label>Esmolol</arm_group_label>
    <other_name>b adrenergic antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>effect of dexmedetomidine on intraoperative sympathetic control and on extubation conditions.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>alpha adrenergic agonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ASA physical status 1-3

          -  Glasgow Coma Scale:13-15

          -  Hunt-Hess: 0-3

        Exclusion Criteria:

          -  Patients with ASA physical status &gt;3,

          -  Body Mass Index (BMI) over 30,

          -  indication for rapid sequence induction,

          -  any contraindication for receiving b-blocker,

          -  Glasgow Coma Scale (GCS) &lt;13,

          -  history of drug abuse,

          -  neurologic deficit or preoperatively foreseen delayed extubation,

          -  preoperative heart rate&lt;45.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Irene Asouhidou, MD, PhD</last_name>
    <email>iasouh@aol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dimitris Zosimidis, MD</last_name>
    <email>d.zosimidis@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>George Papanikolaou General Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>55133</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Asouhidou, MD, PhD</last_name>
      <phone>00302310452560</phone>
      <email>iasouh@aol.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <results_reference>
    <citation>Tanskanen PE, Kyttä JV, Randell TT, Aantaa RE. Dexmedetomidine as an anaesthetic adjuvant in patients undergoing intracranial tumour surgery: a double-blind, randomized and placebo-controlled study. Br J Anaesth. 2006 Nov;97(5):658-65. Epub 2006 Aug 16. Erratum in: Br J Anaesth. 2006 Dec;97(6):908.</citation>
    <PMID>16914460</PMID>
  </results_reference>
  <results_reference>
    <citation>Grillo P, Bruder N, Auquier P, Pellissier D, Gouin F. Esmolol blunts the cerebral blood flow velocity increase during emergence from anesthesia in neurosurgical patients. Anesth Analg. 2003 Apr;96(4):1145-9, table of contents.</citation>
    <PMID>12651674</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>George Papanicolaou Hospital</investigator_affiliation>
    <investigator_full_name>Asouhidou Irene</investigator_full_name>
    <investigator_title>Consultant anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>esmolol</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>opioids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Adrenergic Agents</mesh_term>
    <mesh_term>Esmolol</mesh_term>
    <mesh_term>Adrenergic Agonists</mesh_term>
    <mesh_term>Adrenergic alpha-Agonists</mesh_term>
    <mesh_term>Adrenergic Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

